Sansure Biotech Inc (688289) — Capital Reinvestment Ratio
Latest as of September 2025:
1.06x
Sansure Biotech Inc (688289) has a Capital Reinvestment Ratio of 1.06x as of September 2025, meaning it reinvests 1% of its operating cash flow (CN¥59.72 Million) in capital expenditures (CN¥63.08 Million). See 688289 FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
1.06x
Capex / Operating Cash Flow
Operating Cash Flow
CN¥59.72 Million
CNY
Capital Expenditures
CN¥63.08 Million
CNY
Data as of
Sep 2025
Most recent filing
Sansure Biotech Inc Capital Reinvestment Ratio (2018–2025)
This chart tracks Sansure Biotech Inc's Capital Reinvestment Ratio across 8 annual periods.
Annual Capital Reinvestment Ratio for Sansure Biotech Inc (2018–2025)
Year-by-year Capital Reinvestment Ratio for Sansure Biotech Inc from 2018 to 2025. For live market cap and broader valuation context, see Sansure Biotech Inc (688289) total market value.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 2.01x | CN¥183.96 Million | CN¥369.77 Million | ▲ +31.0% |
| 2024 | 1.53x | CN¥274.45 Million | CN¥421.10 Million | ▼ -55.8% |
| 2023 | 3.47x | CN¥112.82 Million | CN¥391.35 Million | ▲ +1488.4% |
| 2022 | 0.22x | CN¥2.56 Billion | CN¥558.83 Million | ▲ +9.9% |
| 2021 | 0.20x | CN¥1.88 Billion | CN¥372.86 Million | ▲ +383.0% |
| 2020 | 0.04x | CN¥2.64 Billion | CN¥108.67 Million | ▼ -97.3% |
| 2019 | 1.52x | CN¥22.41 Million | CN¥34.14 Million | ▼ -53.4% |
| 2018 | 3.27x | CN¥10.07 Million | CN¥32.90 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow